谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Rationale and Design of the 2 by 2 Factorial Design GnG-trial: a Randomized Phase-Iii Study to Compare Two Schedules of Gemtuzumab Ozogamicin As Adjunct to Intensive Induction Therapy and to Compare Double-Blinded Intensive Postremission Therapy with or Without Glasdegib in Older Patients with Newly Diagnosed AML

Jaramillo Sonia,Krisam Johannes,Le Cornet Lucian,Kratzmann Markus,Baumann Lukas,Sauer Tim,Crysandt Martina,Rank Andreas,Behringer Dirk,Teichmann Lino,Görner Martin,Trappe Ralf-Ulrich,Röllig Christoph,Krause Stefan,Hanoun Maher,Hopfer Olaf,Held Gerhard,Buske Sebastian,Fransecky Lars, Leipzig University Hospital,Schliemann Christoph,Schaefer-Eckart Kerstin, Al-Fareh Yousef,Schubert Jörg,Geer Thomas,Kaufmann Martin,Brecht Arne,Niemann Dirk,Kieser Meinhard,Bornhäuser Martin,Platzbecker Uwe,Serve Hubert,Baldus Claudia D.,Müller-Tidow Carsten, Heidelberg University Hospital and German Cancer Research Center

Trials（2021）

引用 5|浏览53
关键词
gemtuzumab ozogamicin,glasdegib,acute myeloid leukemia,measurable residual disease
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要